Healthdirect Free Australian health advice you can count on.

Medical problem? Call 1800 022 222. If you need urgent medical help, call triple zero immediately

healthdirect Australia is a free service where you can talk to a nurse or doctor who can help you know what to do.

beginning of content

Brand name: Tobramycin (DBL)

Tobramycin (DBL) is a medicine containing the active ingredient(s) tobramycin. On this page you will find out more about Tobramycin (DBL), including side effects, age restrictions, food interactions and whether the medicine is subsidised by the government on the pharmaceutical benefits scheme (PBS)

You should seek medical advice in relation to medicines and use only as directed by a healthcare professional. Always read the label. If symptoms persist see your healthcare professional. healthdirect medicines information is not intended for use in an emergency. If you are suffering an acute illness, overdose, or emergency condition, call triple zero (000) and ask for an ambulance.

Reasonable care has been taken to provide accurate information at the time of creation. This information is not intended to substitute medical advice, diagnosis or treatment and should not be exclusively relied on to manage or diagnose a medical condition. Please refer to our terms and conditions.

Active ingredient in this medicine: tobramycin

Information for medicine and pack size:
Tobramycin (DBL) 80 mg/2 mL injection solution, 5 x 2 mL vials

Consumer Medicine Information leaflet:

This leaflet may also be found inside the medicine package. It contains information on side effects, age restrictions and other useful data.

Read leaflet

What this medicine is for

Treatment of the following serious infections caused by susceptible micro-organisms; . central nervous system infections, including meningitis, septicaemia and neonatal sepsis; . gastro-intestinal infections, including peritonitis; . other such significant infections: complicated and recurrent urinary tract infections, such as pyelonephritis and cystitis; . lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis; . skin, bone and soft tissue infections, including burns. May be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgement indicate its use. Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes or urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organism is resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom gram negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. The decision to continue tobramycin therapy should be based upon the results of susceptibility studies, severity of the infection, and the important additional concepts discussed under the 'Warnings' section in the product information. INDICATIONS AS AT 30 APR 04 : Tobramycin is indicated in the treatment of the following serious infections caused by susceptible micro-organisms: central nervous system infections, including meningitis; septicaemia and neonatal sepsis; gastro-intestinal infections, including peritonitis; complicated and recurrent urinary tract infections such as pyelonephritis and cystitis; lower respiratory tract infections, including pneumonia, bronchopneumonia and acute bronchitis; bone, skin and skin structure infections, including burns. Tobramycin may be considered in serious staphylococcal infections for which penicillin or other less potentially toxic drugs are contraindicated and when bacterial susceptibility testing and clinical judgement indicate its use. Aminoglycosides, including tobramycin, are not indicated in uncomplicated initial episodes or urinary tract infections unless the causative organisms are not susceptible to antibiotics having less potential toxicity. Bacterial cultures should be obtained prior to and during treatment to isolate and identify aetiologic organisms and to test their susceptibility to tobramycin. If susceptibility tests show that the causative organism is resistant to tobramycin, other appropriate therapy should be instituted. In patients in whom gram negative septicaemia, neonatal sepsis, or meningitis is suspected, including those in whom concurrent therapy with a penicillin or cephalosporin and an aminoglycoside may be indicated, tobramycin therapy may be initiated before results of susceptibility studies are obtained. The decision to continue tobramycin therapy should be based upon the results of susceptibility studies, severity of the infection, and the important additional concepts discussed under PRECAUTIONS.

Table of characteristics
Table of characteristics
Active ingredient
Visual appearance A clear, colourless solution.
Dosage Form Injection, solution
Route of administration Intramuscular
Medicine schedule
5x80mg/2mL: Prescription Only Medicine, or Prescription Animal Remedy

There is one type of pack available.

Pack type 1
Pack type 1
Type Vial
Storage temperature Store below 25 degrees Celsius
Storage conditions Protect from Light
Life time 2 Years
This medicine was verified as being available on the PBS (Pharmaceutical Benefits Scheme) on 1 November 2017

The PBS provides a list of government subsidised medicines available to be dispensed to patients. Further information can be found on the Pharmaceutical Benefits Scheme website.

Go to PBS site

Is this medication banned in sport?

Check if you can use your medicine whilst playing sport. Search the Australian Sports Anti-Doping Authority (ASADA) database that provides information about the prohibited status of specific medications and/or the active ingredient based on the current World Anti-Doping Agency (WADA) Prohibited List.

Go to ASADA site

The information displayed on this page is authored by Healthdirect Australia, or obtained from trusted sources.

Need more information?

These trusted information partners have more on this topic.

Found 7 results

Tobramycin Injection BP (DBL) | myVMC

Tobramycin Injection is used to treat severe infections, including meningitis and septicaemia and neonatal sepsis. It is an antibiotic.

Read more on myVMC – Virtual Medical Centre website

DBL Amikacin Injection (Solution for injection) - myDr.com.au

DBL Amikacin Injection (Solution for injection) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Piperacillin and Tazobactam Injection Powder for infusion - myDr.com.au

DBL Piperacillin and Tazobactam Injection Powder for infusion - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Cephalothin Sodium for Injection (Powder for injection) - myDr.com.au

DBL Cephalothin Sodium for Injection (Powder for injection) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Cisplatin Injection (Solution for infusion) - myDr.com.au

DBL Cisplatin Injection (Solution for infusion) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Carboplatin Injection (Solution for infusion) - myDr.com.au

DBL Carboplatin Injection (Solution for infusion) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

DBL Vancomycin Hydrochloride for Intravenous Infusion (Powder for infusion) - myDr.com.au

DBL Vancomycin Hydrochloride for Intravenous Infusion (Powder for infusion) - Consumer Medicines Information leaflets of prescription and over-the-counter medicines

Read more on myDr – Consumer Medicine Information website

Healthdirect 24hr 7 days a week hotline

24 hour health advice and information you can count on

1800 022 222

Government Accredited with over 140 information partners

We are a government-funded service, providing quality, approved health information

Australian Government, health department logo ACT Government logo New South Wales government, health department logo Northen Territory Government logo Government of South Australia, health department logo Tasmanian government logo Government of Western Australia, health department logo
Feedback